Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy Study of Adalimumab to Treat Interstitial Cystitis

This study has been completed.
Information provided by (Responsible Party):
Philip C. Bosch, M.D., ICStudy, LLC Identifier:
First received: February 14, 2011
Last updated: July 12, 2015
Last verified: July 2015

The purpose of this study is to evaluate an investigational treatment for interstitial cystitis. Interstitial cystitis is a chronic bladder disease that includes the following symptoms: Urinary frequency during the day,urinary frequency at night, urinary urgency and bladder discomfort relieved by voiding.

Presently, there is no cure for interstitial cystitis. The response to current treatments is poor. Patients with interstitial cystitis have a poorer quality of life. The cause of interstitial cystitis is unknown. This study is evaluating the drug Humira® (adalimumab) for improving the symptoms of patients with interstitial cystitis. Humira® is an injectable anti-inflammatory medication that has been available for use since December 31, 2002. Humira® has been FDA approved for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, and Crohn's disease. These diseases have similar characteristics to interstitial cystitis. This study will evaluate an investigational use of Humira® for the treatment of interstitial cystitis.

Condition Intervention Phase
Interstitial Cystitis
Drug: Adalimumab
Other: inactive drug
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: An Investigator Initiated, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Humira® (Adalimumab) For The Treatment of Interstitial Cystitis(IC)

Resource links provided by NLM:

Further study details as provided by ICStudy, LLC:

Primary Outcome Measures:
  • O'Leary-Santa Interstitial Cystitis Symptom Index and Problem Index (OSPI) Score [ Time Frame: Baseline/12 Weeks ]
    Improvement in the O'Leary Sant Symptom and Problem Index from baseline to week 12 Total scores on a scale range: 0-36 (0, meaning no symptoms to 36, meaning the most severe symptoms)

Secondary Outcome Measures:
  • Interstitial Cystitis Symptom Index (ICSI) [ Time Frame: Baseline/ 12 weeks ]
    Improvement in O'Leary Sant Interstitial Cystitis Symptom Index (ICSI) Total scores on a range scale: 0-20 (0, meaning no symptoms, to 20, meaning the most severe symptoms)

  • Interstitial Cystitis Problem Index (ICPI) [ Time Frame: Baseline/12 Weeks ]
    Improvement in O'Leary Sant Interstitial Cystitis Problem Index (ICPI) Total scores on a scale: 0-16 (0, meaning no symptoms, to 16, meaning the most severe symptoms)

  • Pelvic Pain Urgency/Frequency (PUF) Score [ Time Frame: Baseline12 Weeks ]
    Pelvic Pain, Urgency/Frequency Symptom Scale Total scores on a scale range: 0-35 (0, meaning no symptoms, to 35, meaning the most severe symptoms)

  • Global Response Assessment (GRA) [ Time Frame: Measured at12 Weeks ]

    Percent(%) of patients who reported 50% or greater overall improvement in their condition.

    Score on a scale range (improvement 0%-100%)

Enrollment: 43
Study Start Date: March 2011
Study Completion Date: July 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: adalimumab
Adalimumab 80mg subcutaneous loading dose followed by 40 mg subcutaneous every 2 weeks for 12 weeks
Drug: Adalimumab
80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
Other Name: Humira
Placebo Comparator: Inactive drug
Placebo in identical syringe subcutaneous every 2 weeks for 12 weeks
Other: inactive drug
80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
Other Name: placebo

Detailed Description:
Interstitial cystitis (IC) is a chronic disabling bladder syndrome characterized by urinary frequency, nocturia, urinary urgency, and pain with bladder filling—relieved by emptying. There is no cure for IC and the treatment options are suboptimal. Patients with IC report significant negative effects on their physical and mental quality of life. The etiology of IC is unknown. Certain aspects of IC suggest that autoimmunity may play a role in initiating or sustaining the chronic inflammatory response. Bladder biopsies of patients with IC demonstrate an increase number of mast cells. Mast cell activation with the release of tumor necrosis factor (TNF) may mediate this bladder inflammation. Humira® (adalimumab) is a medication that blocks the effect of TNF. Humira® (adalimumab) is FDA approved for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, and Crohn's disease. These diseases are similar to IC. In this study, the hypothesis being tested is that Humira® (adalimumab) will show efficacy at reducing the symptoms of IC.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males or females ≥18 and ≤ 65 years of age previously diagnosed with Interstitial Cystitis
  • Currently have symptoms of urinary urgency, frequency or pain for more than 6 months
  • Urinating at least 7 times a day or having some urgency or pain (measured on linear analog scales)
  • Must be post-menopausal or surgically sterile or willing to use an adequate form of birth control
  • Not pregnant or lactating
  • Capable of voiding independently
  • Willing to provide informed consent to participate

Exclusion Criteria:

  • Have symptoms that are presently relieved on other medications for interstitial cystitis
  • Have absence of nocturia
  • Have symptoms that are relieved by antimicrobials or antibiotics.
  • Have a body mass index (BMI) of >39 kg/m2
  • Have uncontrolled hypertension
  • Have Type I or type 2 diabetes
  • Have active Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus (HIV) infection, or who are known carriers (Hepatitis B) at Screening
  • Have a positive tuberculosis test at screening
  • Have had a urinary tract infection for 6 weeks
  • Have had bacterial cystitis in previous 3 months
  • Have had previous exposure to Humira® (adalimumab)
  • Have taken investigational medication within 30 days of screening
  • Have any other condition/disease which, in the opinion of the investigator, could compromise subject safety or confound the interpretation of study results
  • Are unable or unwilling to comply with protocol requirements
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01295814

United States, California
Philip C. Bosch, MD
Escondido, California, United States, 92025
Sponsors and Collaborators
ICStudy, LLC
Principal Investigator: Philip C Bosch, MD
  More Information

Responsible Party: Philip C. Bosch, M.D., Urologist, ICStudy, LLC Identifier: NCT01295814     History of Changes
Other Study ID Numbers: IMM 10-0061
Study First Received: February 14, 2011
Results First Received: July 20, 2013
Last Updated: July 12, 2015

Keywords provided by ICStudy, LLC:
Interstitial cystitis

Additional relevant MeSH terms:
Cystitis, Interstitial
Urinary Bladder Diseases
Urologic Diseases
Anti-Inflammatory Agents
Antirheumatic Agents processed this record on May 22, 2017